SimBioSys® Elevates Leadership Team as It Receives First FDA Clearance for Digital Precision Medicine Platform, TumorSight™
– Seasoned HealthTech Executive Jyoti Palaniappan Appointed as Chief Commercial Officer CHICAGO–(BUSINESS WIRE)–SimBioSys®, a trailblazing TechBio... Read more.
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0%... Read more.
CI Global Asset Management Announces Confirmed Annual Reinvested Distributions for JFT Strategies Fund
NOT FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO–(BUSINESS WIRE)–$CIX #CIFinancial—CI... Read more.
Boxlight Corporation Board of Directors Announces Leadership Changes
Independent Director Dale Strang Appointed as Interim CEO; Michael Pope Departs as Chief Executive Officer Wayne Jackson Appointed Chairman of the Board Company... Read more.
Marti Announces Completion of Redemption of Outstanding Warrants
ISTANBUL–(BUSINESS WIRE)–Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye’s leading mobility app, today announced... Read more.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today... Read more.
Green Plains Inc. and Green Plains Partners LP Announce Unitholder Approval of Merger
OMAHA, Neb.–(BUSINESS WIRE)–Green Plains Inc. (NASDAQ: GPRE) (“Green Plains”) and Green Plains Partners LP (NASDAQ: GPP) (the “Partnership”)... Read more.
2023 Benchmark Study of 5G Four Component Carrier in Rural America – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Volume 35: American Broadband – a Benchmark Study of 5G Four Component Carrier in Rural America” report... Read more.
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Global Phase 3 studies started for bomedemstat (LSD1 inhibitor), nemtabrutinib (BTK inhibitor), MK-2870 (anti-TROP2 ADC) and MK-5684 (CYP11A1 inhibitor) Comprehensive... Read more.
Kinsale Capital Group Announces Board and Management Changes
RICHMOND, Va.–(BUSINESS WIRE)–Kinsale Capital Group, Inc. (NYSE: KNSL) (the “Company”) announced today changes to its Board of Directors (the “Board”)... Read more.